Danvatirsen sodium is under clinical development by AstraZeneca and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData, Phase II drugs for Oral Cavity (Mouth) Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Danvatirsen sodium LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Danvatirsen sodium overview
Danvatirsen sodium (IONIS-STAT3) is under development for the treatment of recurrent and metastatic head and neck cancer squamous cell carcinoma, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer, laryngeal cancer, advanced solid malignancies, pancreatic cancer, non-small cell lung cancer, colorectal cancer. It is administered through intravenous route. The drug candidate is a 16 oligonucleotide antisense molecule (ASO) targeting the 3' untranslated part of signal transducer and activator of transcription 3 (STAT3). It is based on FLAME discovery engine. It was also under development for the treatment of metastatic hepatocellular carcinoma, gastrointestinal cancer, ovarian cancer, malignant ascites and diffuse large B-Cell lymphoma. It is being developed based on FLAME (Flamingo Long non-coding RNA (LncRNA) Antisense Mining Engine) technology platform.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Danvatirsen sodium’s drug-specific PTSR and LoA scores, buy the report here.